Whanin Pharm Cash Flow Quality Index
Whanin Pharm cash flow quality index. Whanin Pharm (016580) has a Cash Flow Quality Index of 1.20x as of June 2026. Operating cash flow of ₩9.26 Billion exceeds net income of ₩7.70 Billion, indicating high earnings quality where cash backs reported profits. Explore Whanin Pharm debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Whanin Pharm (2009–2025)
Cash flow quality index of Whanin Pharm from 2009 to 2025. Historical Cash Flow Quality Index for Whanin Pharm across 14 annual periods. Values consistently above 1.0x indicate high-quality earnings. See Whanin Pharm balance sheet independence to measure how much of total assets are equity-financed.
Whanin Pharm Cash Flow Quality Index by Year (2009–2025)
Whanin Pharm cash flow quality index by year from 2009 to 2025. Year-by-year earnings quality comparison for Whanin Pharm. For the full cash flow conversion analysis, see cash flow conversion of Whanin Pharm.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.67x | ₩9.04 Billion | ₩13.60 Billion | ▼ -22.7% |
| 2024 | 0.86x | ₩20.69 Billion | ₩24.06 Billion | ▲ +10.4% |
| 2023 | 0.78x | ₩23.20 Billion | ₩29.77 Billion | ▲ +10.6% |
| 2022 | 0.70x | ₩16.85 Billion | ₩23.92 Billion | ▼ -46.8% |
| 2021 | 1.32x | ₩35.32 Billion | ₩26.66 Billion | ▲ +36.2% |
| 2020 | 0.97x | ₩22.75 Billion | ₩23.39 Billion | ▼ -26.4% |
| 2019 | 1.32x | ₩24.73 Billion | ₩18.70 Billion | ▲ +63.1% |
| 2018 | 0.81x | ₩17.45 Billion | ₩21.52 Billion | ▼ -6.1% |
| 2017 | 0.86x | ₩23.48 Billion | ₩27.17 Billion | ▼ -28.5% |
| 2016 | 1.21x | ₩19.82 Billion | ₩16.40 Billion | ▼ -9.5% |
| 2012 | 1.34x | ₩21.11 Billion | ₩15.80 Billion | ▲ +29.2% |
| 2011 | 1.03x | ₩15.12 Billion | ₩14.61 Billion | ▲ +18.0% |
| 2010 | 0.88x | ₩15.12 Billion | ₩17.24 Billion | ▼ -32.0% |
| 2009 | 1.29x | ₩18.61 Billion | ₩14.43 Billion | — |